No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - The chief financial officer of consumer health company Haleon is to step down after three years and will be replaced by Tate & Lyle's CFO Dawn Allen.
The company, known for brands like Sensodyne, Centrum and Panadol, announced on Wednesday that Tobias Hestler has decided to leave "to better balance work demands with the management of a long-term health condition".
He will leave the company in November, having served nearly three years after joining in December 2021.
Hestler will be succeeded by Dawn Allen, the current CFO at Tate & Lyle and former CFO at Mars Inc, who also serves on the board at ITV.
Allen, who will receive an annual salary of £730,000 along with an annual bonus and long-term incentive plans, has "extensive consumer and international experience and will be a great addition to our executive team", said Haleon's chief executive Brian McNamara.
Allen said she was "very excited" to join Haleon. "Its clear purpose and fascinating journey through separation and beyond sets a strong foundation for the future. I am looking forward to help shape the next phase of the journey," she said.
In a separate statement, ingredients group Tate & Lyle said: "The board has begun a process to appoint a successor to Mrs Allen and a further announcement will be made in due course."
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.